Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5463_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •About the Editor
- •Contents
- •Contributors
- •1.1.4 Components of niosome
- •1.1.5 Factors affecting niosomes
- •Preface
- •Abstract
- •1.1 Introduction
- •1.1.1 Why niosome?
- •1.1.2 Advantages of niosome
- •1.1.3 Structure of niosome
- •1.2 Applications of niosome
- •1.2.2 Niosomes for the delivery of therapeutics
- •1.2.3 Niosomes in biomedical applications
- •1.3 Conclusions and future prospects
- •Keywords
- •References
- •Abstract
- •2.1 Introduction
- •2.2 Conclusions
- •Acknowledgments
- •Keywords
- •References
- •Abstract
- •3.1 Introduction
- •3.2.1 Parameters involved in electrospinning process
- •3.2.2 Biomaterials for electrospinning
- •3.3 Electrospun nanofibers as drug delivery systems
- •3.3.1 Blending electrospinning
- •3.3.2 Emulsion electrospinning
- •3.3.3 Coaxial electrospinning
- •3.3.4 Surface modifications
- •3.4 Electrospun nanofibers for tissue engineering
- •3.4.1 Electrospun nanofibers for hard tissue engineering
- •3.5 Cancer diagnosis and therapy
- •3.6 Concluding remarks and future perspectives
- •Keywords
- •References
- •4. Natural Biocarriers for Brain Targeting
- •Abstract
- •4.1 Introduction
- •4.1.1 Central nervous system
- •4.2 Biocarriers
- •4.2.1 Carbohydrates carriers
- •4.2.2 Protein carriers
- •4.2.3 Exosomes
- •4.3 Conclusions and perspectives
- •Keywords
- •References
- •Abstract
- •5.1 Introduction
- •5.2 Synthesis of graphene family nanomaterials
- •5.2.1 Graphene synthesis
- •5.2.2 GO and rGO Syntheses
- •5.2.3 GQd synthesis
- •5.4 Drug delivery and biomedical applications
- •5.4.1 Drug delivery
- •5.4.2 Gene delivery
- •5.4.3 Bioimaging
- •5.4.4 Photothermal therapy
- •5.4.5 Tissue engineering
- •5.5 Summary and future prospect
- •Keywords
- •References
- •6. Nanotechnology in Gene Delivery
- •Abstract
- •6.1 Introduction
- •6.2 Gene delivery
- •6.3 Nanotechnology in gene delivery
- •Keywords
- •References
- •Abstract
- •7.1 Introduction
- •7.2 Additive manufacturing in pharmacology
- •7.2.1 Extrusion-based 3D printing techniques
- •7.2.2 Stereolithography
- •7.2.3 Selective laser sintering
- •7.2.4 Binder jet printing
- •7.3 Most common polymers
- •7.3.1 Natural polymers
- •7.3.2 Synthetic polymers
- •7.3.2.5 Polyvinylpyrrolidone
- •7.4 Common 3D-printed dosage forms
- •7.4.1 Scaffolds
- •7.4.2 Tablets
- •Keywords
- •References
- •7.4.3 Microneedles
- •7.4.4 Capsule
- •7.4.5 Films
- •7.5 Main factors in drug delivery
- •7.5.1 Nature of polymers
- •7.5.2 Matrix permeability
- •7.5.3 Polymer blends
- •7.5.4 Specific surface area
- •7.5.5 Infill density and patterns
- •7.5.6 Pores
- •7.5.7 Cross-linking
- •7.5.8 Coating
- •7.5.9 Core/shell and multicompartment
- •7.6 Final considerations and future perspectives
- •Abstract
- •8.1 Introduction
- •8.2.1 Polymer solution concentration and viscosity
- •8.2.2 Molecular weight of polymer
- •8.2.3 Surface tension
- •8.2.4 Electrical conductivity
- •8.2.5 Applied voltage
- •8.2.6 Feed rate/flow rate
- •8.2.7 Temperature and humidity
- •8.3 Method of preparation for nanofibers
- •8.3.1 Electrospinning
- •8.3.2 Self-assembly
- •8.3.3 Phase separation
- •8.3.4 Drawing of nanofibers
- •8.3.5 Template synthesis
- •8.4 Biomedical applications of nanofibers
- •8.4.1 Wound dressing
- •8.4.2 Tissue engineering
- •8.4.3 In cancer therapy
- •8.4.4 Miscellaneous
- •8.5 Drug delivery application
- •8.5.1 Antihypertensive drug
- •8.5.2 Antimicrobial drug
- •8.5.3 Growth hormone
- •8.5.4 Miscellaneous
- •8.6 Conclusion
- •Keywords
- •References
- •Abstract
- •9.1 Introduction
- •9.2 Tissue engineering
- •9.3 Nanotechnology
- •9.4 Polymeric scaffolds in tissue engineering
- •9.5 Challenges
- •Keywords
- •References
- •Abstract
- •10.1 Introduction
- •10.2 Ideal properties of bioceramics
- •10.2.1 Mechanical property
- •10.2.2 Porosity, pore size, and shape
- •10.2.3 Biocompatibility and biodegradability
- •10.2.4 Osteoconductivity and osseointegrity
- •10.3 Bioceramics in orthopedic applications
- •10.4 Bioceramics in maxillofacial surgery
- •10.5 Bioceramic in drug delivery applications
- •10.6 Doped bioceramic in biomedical application
- •10.7 Conclusions
- •10.8 Future direction
- •Acknowledgments
- •Keywords
- •References
- •Index

38
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
-
(Kirkham and Davis, 2015). Despite promising laboratorial outcomes, data
treatment are still limited (Mehta, 2018).
In addition to physical activity , both cancer and the cardiotoxicity caused
by chemotherapy drugs can be modulated by healthy and balanced diets and
nutritional therapies, based on antioxidant supplements, because they are
and, consequently, reducing the oxidative stress (Saha et al., 2017).
-
-
have been used in medicine to prevent and treat several diseases, including
2011).
-
(Su et al., 2022).
Nanoparticles containing chemotherapy drugs act by targeting the tumor
microenvironment and niche, releasing the active ingredients in the tumor
tissues, thus reducing toxicity in heart tissues (Su et al., 2022).
micelles, dendrimers, and hydrogels) used as drug carriers are the prevention
-
in vital organs, such as the heart (Su et al., 2022).

Advances for Medical Applications in Breast Cancer and Cardiotoxicity
39
in-vitro
FIGURE 2.1
2.1.1 BENEFITS OF PHYSICAL ACTIVITY DURING CHEMOTHERAPY
IN PATIENTS WITH BREAST CANCER
Exercises can reduce breast cancer and its recurrence and help increase

40
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
(Scott et al., 2018).
physical exercise during chemotherapy treatments (de Boer et al., 2017).
sessions (de Boer et al., 2019).
-
al., 2021), and only one study applied the intervention in a tele-monitored
2019).
interventions based on exercises can reduce the cardiotoxicity caused by

Advances for Medical Applications in Breast Cancer and Cardiotoxicity
41
-
2018b).
-
-
exercises can prevent anthracycline-induced cardiotoxicity and anti-HER2
-

42
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
diverse aspects.
2.1.2 PHYSICAL EXERCISE IN THE PREVENTION OF
CARDIOTOXICITY
-
endometrium, esophagus, stomach, kidney, bladder, and lung, and reduces
mortality in patients that survived breast, prostate, colon, and rectum neopla-
these patients (Herdy et al., 2014).
-

Advances for Medical Applications in Breast Cancer and Cardiotoxicity
43
-
-
anthracycline-induced toxicity in the cardiac muscle are still lacking (Maia
-
group (n = 13) compared to the control (n = 11), despite improvements in
-
2018).
On the other hand, a previous and very similar study conducted by the

44
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
(VO
2 max
2 peak
in the intervention group.
and cardiac output (Hornsby et al., 2014).
-
-
2 max
-
A later research study conducted by Hiraoui et al. (2019) assessed 32
-
-

Advances for Medical Applications in Breast Cancer and Cardiotoxicity
45
are more likely to complete chemotherapy (An et al., 2021).
-
lute VO
2 peak
cardiorespiratory responses.
-
-
-
(Antunes et al., 2019).

46
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
-
by echocardiogram (Jacquinot et al., 2017).
-
-
elucidate the pathophysiological mechanisms involved, and determine the
2.1.3 NUTRITIONAL SUPPLEMENTATION IN BREAST CANCER AND
PROTECTION AGAINST CARDIOTOXICITY
and Suh, 2011), vitamin D (Lee et al., 2021), carotenoids such as curcumin
Ganoderma lucidum (Xu et al.,
such as Ceylon cinnamon (Cinnamomum zeylanicum Blume) (Sandamali et

Advances for Medical Applications in Breast Cancer and Cardiotoxicity
47
in-vivo animal
et al., 2020). It should also be noted that, depending on the type and concen-
-
genesis in animal models (Smolarek and Suh, 2011).
Suh, 2011).
reported as a cardioprotective agent. It reduced Dox-induced cardiotoxicity,
diminished ROS and mitochondrial damage, and did not diminish Dox-
(Lee et al., 2021).
Curcuma longa
oral administration (Saghatelyan et al., 2020).
Соседние файлы в папке Библиотека им академика М.И. Перельмана
